

Case Study: Patient Update #2

Debbie Davila, MSN, RN

Nurse Consultant/Educator

Heartland National TB Center

Case Study Summary

- 65-year-old male, Air Force veteran with a history of untreated hepatitis C. He has a "cough that will not go away," and he has been "been feeling tired."
- Abnormal CXR, reveals extensive bilateral cavitary lesions.
- History of positive TST "years ago" when he was in the military.
- TB clinic visit reveals:
 - AFB smear (+), Xpert (+)
 - history of alcohol use
 - unstable housing
 - untreated HCV
 - baseline LFTs = ALT 45 units/L, and AST 60 units/L.
 - started RIPE by DOT
 - visit #10 LFTs were elevated
 - Medications on HOLD



Case Study....continued

Cannot restart anti-TB therapy until LFT's <2 times upper limit of normal

- Re-challenge medications
 - Introduce one drug at a time
- Liver Friendly Regimen



Watch closely.





Case Study Continued.....

- Liver Friendly Regimen was started when LFTs were less than
 2 x upper limit of normal (Linezolid, EMB, Moxifloxacin)
- •How do we monitor this patient for the remainder of TB treatment?
 - Monitored LFTs closely
 - Encourage adherence
 - Re-educate patient to abstain from alcohol while on TB treatment
 - Review adverse effects
 - Instruct patient to self monitor for side effects/adverse reactions while on meds





Most importantly:

Instruct patient to stop taking TB medications immediately and seek medical attention if symptoms of hepatitis occur again.


Case Study....continued

The PHN closely assesses the patient for signs and symptoms of liver toxicity during the remainder of TB treatment and the patient completed TB treatment successfully with 9 months of TB treatment.





Monitoring Tools



MDR-TB Assessment Checklist



2-Some patients become depressed due to skin color changes


Heartland National TB Center
 https://www.heartlandntbc.org/consultation/



Monitoring Tools

Texas Department of State Health Services

https://dshs.texas.gov/disease/tb/forms.shtm



Teeter/Fall to Left or Right when standing (eyes closed Unusual bleeding (nose, gums, stool, urine, etc.) o

Visual problems/changes in vision*** - EMB, RBT

easy bruising - RIF, RPT+

Kansas Department of Health and Environment

https://www.kdhe.ks.gov/DocumentCenter/View/3833/Tuberculosis-Medication-Monitoring-Report-PDF

MEDICATION MONITORING REPORT

The person receiving preventive therapy or a responsible adult caring for a child on preventive therapy should be questioned concerning the following symptoms or signs consistent with liver damage or other adverse effects.

Date of interview																								
	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N
Feeling of fatigue					Т		Т		Т				Т							Т				T
Loss of appetite																								
Nausea			\vdash		Н		Н		Н		\vdash		Н				Т			Н		Н		\vdash
Vomiting			\vdash		Т		Н		Н											Н		Н		Н
Headache		H			Т		Н													Н				H
Numbness of feet/hands	\vdash		Т		Н		Н		Н				Т							Н		Т		Т
Itching or rash					Т		Н													Н				H
Trouble voiding			\vdash		Н		Н		Н				Н							Н		Н		\vdash
Dark urine	T		\vdash		Т		Н		Н											Н		Н		Н
Jaundiced skin																				Н				H
Jaundiced sclera	\vdash		\vdash	H	\vdash		\vdash		\vdash			\vdash	\vdash	\vdash						\vdash				H
Vision screening	\vdash		\vdash				\vdash													\vdash				H
Hearing screening	\vdash		\vdash				\vdash													\vdash				H
Interviewer:	\vdash	_	\vdash	_	Н	_	\vdash	_		_		_		_		_		_		_		_		_

If any of these or other signs or symptoms occur during preventive therapy, patients should repeatedly be advised to report immediately to the clinic or health care provider.

Of individuals receiving isoniazid, 10% to 20% will develop some mild abnormality of liver function tests, e.g., an elevated aspartate aminotransferase (AST; SGOT). These abnormalities tend to resolve even if isoniazid is continued.


Persons with history of hepatic disease or other persons at risk of hepatitis:

These individuals, especially alcohol abusers, injection drug users and persons taking any other concurrent medications, should have baseline liver function tests, with subsequent biochemical monitoring, according to the patient's risk of hepatitis and at the physician's discretion.

If any of these results exceed 3 to 5 times the upper limit of normal, discontinuation of isoniazid should be strongly

Joint Product Page Centers of Excellence TB Training and Education Products

https://sntc.medicine.ufl.edu/rtmccproducts.aspx





Vision Screening

Ishihara Test


Test for red-green color blindness, and was created by Dr. Shinobu Ishihara


Consists of a set of 38 colored dotted plates (called Ishihara plates) that either contain a number or path-shaped design.

Snellen chart

Eye chart that can be used to measure visual acuity








Peripheral Neuropathy Tool

Peripheral Neuropathy Evaluation









Group Exercise





